Control Bionics has received approval from the Centers for Medicare & Medicaid Services (CMS) for a new Healthcare Common Procedure Coding System (HCPCS) code for the NeuroNode sensor.
With the approval, the NeuroNode now qualifies for a $4,300 reimbursement, enhancing its accessibility in the US market.
Related: Cresilon secures second clearance for blood stemming Traumagel
The HCPCS Level II code, E2513, categorises NeuroNode as an “Accessory for speech generating device, electromyographic sensor”, acknowledging its unique EMG and 3D spatial movement capabilities.
The NeuroNode wireless, wearable sensor technology offers a breakthrough for users with conditions such as ALS and cerebral palsy, providing a non-invasive method for computer access and communication.
Its ability to interpret EMG signals and movements allows users to accurately control speech-generating devices, offering a transformative communication solution.
The approval also presents an opportunity to establish a wholesale distribution model in the US, targeting the significant market of individuals diagnosed with ALS or cerebral palsy.
The HCPCS E2513 code will be effective from 1 October 2024, enabling Control Bionics and its US partners to apply for the reimbursement.
Control Bionics will also begin negotiations with private insurers to cover the NeuroNode as an in-network device.
Control Bionics CEO Jeremy Steele said: “The introduction of the new HCPCS code for NeuroNode marks a significant milestone, not just for Control Bionics but for the countless individuals who rely on our technology to communicate and regain control of their lives.
“This recognition will greatly enhance accessibility, making it easier for patients to obtain the necessary support and devices through their insurance provider.”
“This code will expand our market reach, enabling us to bring our life-changing technology to a larger audience, and driving our mission to enhance communication and independence for those with severe disabilities.”
